

SEP - 4 2001

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Manufacturera Dental Continental C/O Mr. Gary Mocnik Official Correspondent Gary Mocnik & Associates 27881 La Paz Road, #G 316 Laguna Niguel, California 92677

Re: K011785

Trade/Device Name: Novel Print Cyan Alginates

Regulation Number: 872.3660

Regulatory Class: II Product Code: ELW Dated: June 1, 2001 Received: June 8, 2001

Dear Mr. Mocnik:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements

concerning your device in the <u>Federal Register</u>. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the <u>Electronic Product Radiation Control provisions</u>, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html.

Sincerely yours

Timothy A. Ulatowski

Director

Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

Indication For Use: Intended to be placed on a preformed impression tray and used to reproduce the structure of a patient's teeth and gums. The device is intended to provide models study and for production of restorative prosthetic devices, such as gold inlays and dentures. (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off) Division of Dental, Infection Control,	Device Name:	Novel Print Cyan Alginates
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Concurrence of CDRH, Office of Device Evaluation (ODE) Concurrence of CDRH, Office of Device Evaluation (ODE)	Indication For U	se:
Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR Over-The-Counter Use (Division Sign-Off)	study and for pro	CIII S LCCIII AND GIIMS. The derice is intended to the
Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) Prescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)		
Concurrence of CDRH, Office of Device Evaluation (ODE) rescription Use OR Over-The-Counter Use (Division Sign-Off)	(PLEASE DO MOTUM	
rescription UseOR Over-The-Counter Use (Division Sign-Off)	(- DONOI WK	THE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
rescription UseOR Over-The-Counter Use (Division Sign-Off)		
Over-The-Counter Use (Division Sign-Off)		Concurrence of CDRH, Office of Device Evaluation (ODE)
Over-The-Counter Use (Division Sign-Off)		
Over-The-Counter Use (Division Sign-Off)		
Over-The-Counter Use (Division Sign-Off)	•	
Over-The-Counter Use (Division Sign-Off)		
		OR Over-The-Counter Use
		Susantifice